This site is intended for healthcare professionals

Gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease and reports significant reduction of amyloid plaque.-Genentech/Roche

Read time: 1 mins
Last updated:10th Oct 2021
Published:10th Oct 2021
Genentech/Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the FDA for the treatment of people living with Alzheimer’s disease (AD).
Condition: Alzheimers
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights